Home Healthcare IT Parkinson's Disease Drugs Market

Parkinson's Disease Drugs Market Size, Share & Trends Analysis Report By Mechanism of Action (Dopamine Agonists, Anticholinergic, MAO-B inhibitors, Amantadine, Carbidopa-levodopa, COMT Inhibitors, Other Mechanisms of Action) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Debashree B | Format: | Report Code: SRHI3633DR | Pages: 156
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Regulatory Framework
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  7. ESG Trends
  8. Global Parkinson's Disease Drugs Market Size Analysis
    1. Global Parkinson's Disease Drugs Market Introduction
    2. By Mechanism of Action
      1. Introduction
        1. Mechanism of Action By Value
      2. Dopamine Agonists
        1. By Value
      3. Anticholinergic
        1. By Value
      4. MAO-B inhibitors
        1. By Value
      5. Amantadine
        1. By Value
      6. Carbidopa-levodopa
        1. By Value
      7. COMT Inhibitors
        1. By Value
      8. Other Mechanisms of Action 
        1. By Value
  9. North America Market Analysis
    1. Introduction
    2. By Mechanism of Action
      1. Introduction
        1. Mechanism of Action By Value
      2. Dopamine Agonists
        1. By Value
      3. Anticholinergic
        1. By Value
      4. MAO-B inhibitors
        1. By Value
      5. Amantadine
        1. By Value
      6. Carbidopa-levodopa
        1. By Value
      7. COMT Inhibitors
        1. By Value
      8. Other Mechanisms of Action 
        1. By Value
    3. U.S.
      1. By Mechanism of Action
        1. Introduction
          1. Mechanism of Action By Value
        2. Dopamine Agonists
          1. By Value
        3. Anticholinergic
          1. By Value
        4. MAO-B inhibitors
          1. By Value
        5. Amantadine
          1. By Value
        6. Carbidopa-levodopa
          1. By Value
        7. COMT Inhibitors
          1. By Value
        8. Other Mechanisms of Action 
          1. By Value
    4. Canada
  10. Europe Market Analysis
    1. Introduction
    2. By Mechanism of Action
      1. Introduction
        1. Mechanism of Action By Value
      2. Dopamine Agonists
        1. By Value
      3. Anticholinergic
        1. By Value
      4. MAO-B inhibitors
        1. By Value
      5. Amantadine
        1. By Value
      6. Carbidopa-levodopa
        1. By Value
      7. COMT Inhibitors
        1. By Value
      8. Other Mechanisms of Action 
        1. By Value
    3. U.K.
      1. By Mechanism of Action
        1. Introduction
          1. Mechanism of Action By Value
        2. Dopamine Agonists
          1. By Value
        3. Anticholinergic
          1. By Value
        4. MAO-B inhibitors
          1. By Value
        5. Amantadine
          1. By Value
        6. Carbidopa-levodopa
          1. By Value
        7. COMT Inhibitors
          1. By Value
        8. Other Mechanisms of Action 
          1. By Value
    4. Germany
    5. France
    6. Spain
    7. Italy
    8. Russia
    9. Nordic
    10. Benelux
    11. Rest of Europe
  11. APAC Market Analysis
    1. Introduction
    2. By Mechanism of Action
      1. Introduction
        1. Mechanism of Action By Value
      2. Dopamine Agonists
        1. By Value
      3. Anticholinergic
        1. By Value
      4. MAO-B inhibitors
        1. By Value
      5. Amantadine
        1. By Value
      6. Carbidopa-levodopa
        1. By Value
      7. COMT Inhibitors
        1. By Value
      8. Other Mechanisms of Action 
        1. By Value
    3. China
      1. By Mechanism of Action
        1. Introduction
          1. Mechanism of Action By Value
        2. Dopamine Agonists
          1. By Value
        3. Anticholinergic
          1. By Value
        4. MAO-B inhibitors
          1. By Value
        5. Amantadine
          1. By Value
        6. Carbidopa-levodopa
          1. By Value
        7. COMT Inhibitors
          1. By Value
        8. Other Mechanisms of Action 
          1. By Value
    4. Korea
    5. Japan
    6. India
    7. Australia
    8. Singapore
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
  12. Middle East and Africa Market Analysis
    1. Introduction
    2. By Mechanism of Action
      1. Introduction
        1. Mechanism of Action By Value
      2. Dopamine Agonists
        1. By Value
      3. Anticholinergic
        1. By Value
      4. MAO-B inhibitors
        1. By Value
      5. Amantadine
        1. By Value
      6. Carbidopa-levodopa
        1. By Value
      7. COMT Inhibitors
        1. By Value
      8. Other Mechanisms of Action 
        1. By Value
    3. UAE
      1. By Mechanism of Action
        1. Introduction
          1. Mechanism of Action By Value
        2. Dopamine Agonists
          1. By Value
        3. Anticholinergic
          1. By Value
        4. MAO-B inhibitors
          1. By Value
        5. Amantadine
          1. By Value
        6. Carbidopa-levodopa
          1. By Value
        7. COMT Inhibitors
          1. By Value
        8. Other Mechanisms of Action 
          1. By Value
    4. Turkey
    5. Saudi Arabia
    6. South Africa
    7. Egypt
    8. Nigeria
    9. Rest of MEA
  13. LATAM Market Analysis
    1. Introduction
    2. By Mechanism of Action
      1. Introduction
        1. Mechanism of Action By Value
      2. Dopamine Agonists
        1. By Value
      3. Anticholinergic
        1. By Value
      4. MAO-B inhibitors
        1. By Value
      5. Amantadine
        1. By Value
      6. Carbidopa-levodopa
        1. By Value
      7. COMT Inhibitors
        1. By Value
      8. Other Mechanisms of Action 
        1. By Value
    3. Brazil
      1. By Mechanism of Action
        1. Introduction
          1. Mechanism of Action By Value
        2. Dopamine Agonists
          1. By Value
        3. Anticholinergic
          1. By Value
        4. MAO-B inhibitors
          1. By Value
        5. Amantadine
          1. By Value
        6. Carbidopa-levodopa
          1. By Value
        7. COMT Inhibitors
          1. By Value
        8. Other Mechanisms of Action 
          1. By Value
    4. Mexico
    5. Argentina
    6. Chile
    7. Colombia
    8. Rest of LATAM
  14. Competitive Landscape
    1. Parkinson's Disease Drugs Market Share By Players
    2. M&A Agreements & Collaboration Analysis
  15. Market Players Assessment
    1. AbbVie Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Orion Corporation
    3. Amneal Pharmaceuticals Inc.
    4. Boehringer Ingelheim GmbH
    5. Supernus Pharmaceuticals Inc.
    6. GlaxoSmithKline PLC
    7. Teva Pharmaceutical Industries Ltd
    8. Pfizer Inc.
    9. F Hoffmann-La Roche AG
    10. Takeda Pharmaceutical Company Ltd.
  16. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  17. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  18. Disclaimer
Get This Report

Download Free Sample

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.